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Background: Previous studies have suggested that patients’ treatment preferences may inﬂuence treat-
ment outcome. The current study investigated whether preference for either mindfulness-based cog-
nitive therapy (MBCT) or maintenance antidepressant medication (mADM) to prevent relapse in re-
current depression was associated with patients’ characteristics, treatment adherence, or treatment
outcome of MBCT.
Methods: The data originated from two parallel randomised controlled trials, the ﬁrst comparing the
combination of MBCT and mADM to MBCT in patients preferring MBCT (n¼249), the second comparing
the combination to mADM alone in patients preferring mADM (n¼68). Patients’ characteristics were
compared across the trials (n¼317). Subsequently, adherence and clinical outcomes were compared for
patients who all received the combination (n¼154).
Results: Patients with a preference for mADM reported more previous depressive episodes and higher
levels of mindfulness at baseline. Preference did not affect adherence to either MBCT or mADM. With
regard to treatment outcome of MBCT added to mADM, preference was not associated with relapse/
recurrence (χ2¼0.07; p¼ .80), severity of (residual) depressive symptoms during the 15-month follow-up
period (β¼0.08, p¼ .49), or quality of life.
Limitations: The group preferring mADM was relatively small. The inﬂuence of preferences on outcome
may have been limited in the current study because both preference groups received both interventions.
Conclusions: The fact that patients with a preference for medication did equally well as those with a
preference for mindfulness supports the applicability of MBCT for recurrent depression. Future studies of
MBCT should include measures of preferences to increase knowledge in this area.
& 2016 Elsevier B.V. All rights reserved.1. Introduction
Major depressive disorder (MDD) is a common and highly de-
bilitating mental disorder that is characterized by high rates of
relapse or recurrence (Richards, 2011). To date, the most com-
monly used treatment to prevent future episodes of MDD is the
use of maintenance antidepressant medication (mADM). Although
there is evidence that mADM are more effective than placebo in
reducing the risk of relapse (Borges et al., 2014; Kaymaz et al.,(M.J. Huijbers).2008), adherence to mADM is generally low (Bockting et al., 2008)
and the prophylactic effectiveness seems to decrease with the
number of previous episodes (Kaymaz et al., 2008). Therefore, al-
ternative preventive strategies have been developed. For example,
Mindfulness-Based Cognitive Therapy (MBCT; Segal et al. (2012))
signiﬁcantly reduces relapse risk in patients with three or more
previous depressive episodes (Piet and Hougaard, 2011) and ap-
pears to be at least as effective as mADM in the prevention of
relapse (Kuyken et al., 2008; Kuyken et al., 2015; Segal et al., 2010).
This suggests that MBCT offers a viable alternative for patients
preferring a psychological intervention to prevent relapse.
In general, practice guidelines recommend that patients’
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lection of a treatment modality (American Psychiatric Association
(APA), 2010). In the context of the acute phase of depression
treatment, depressed patients have been shown to generally pre-
fer psychological rather than pharmacological treatment (Steidt-
mann et al., 2012; van Schaik et al., 2004). This suggests that many
patients with recurrent depression might prefer psychological
treatment, such as MBCT, over mADM to prevent relapse/
recurrence.
Treatment preferences seem to be related to treatment ex-
pectations and therefore, may contribute to adherence and out-
comes as a non-speciﬁc therapeutic factor (Rutherford et al., 2010).
Although several studies on the acute treatment of depression
have examined the impact of preferences on outcome, results are
inconclusive. A systematic review on treatment preferences in
MDD concluded that preferences may positively affect treatment
initiation and the therapeutic alliance, but have minimal impact on
depression severity outcomes (Gelhorn et al., 2011). In contrast, a
simultaneous meta-analysis indicated a small (Cohen’s d¼0.31)
but signiﬁcant beneﬁt of preference-match in patients with psy-
chiatric problems receiving psychological or pharmacological
therapies (Swift et al., 2011). For the subset of studies speciﬁcally
looking at depression (k¼12), this effect was also small (d¼0.35)
but signiﬁcant. The inconsistency in the literature on the effects of
preference on treatment outcome may be related to differences in
methodology. For example, in an RCT comparing behavioural ac-
tivation and antidepressant medication, preference for psy-
chotherapy inﬂuenced treatment outcome in terms of clinician-
rated depression, but not self-rated depression (Moradveisi et al.,
2014). In addition, the strength of patient preference on a con-
tinuous measure may be more predictive of outcome than pre-
ference-match as a categorical predictor (Raue et al., 2009).
Unlike most patient characteristics, preferences cannot be
randomly allocated because of their intrinsic relationship with the
received treatment. In this way, preferences can affect the external
and internal validity of randomised controlled trials (RCTs) (Cor-
rigan and Salzer, 2003). For instance patients with a strong pre-
ference for psychological treatment are likely to decline RCTs
precluding their preference (van Schaik et al., 2004). Consequently,
RCTs may underestimate the effect of preferences on outcome. In
addition, preferences may affect the internal validity of a trial, for
example because patients who receive a treatment concordant
with their preference are less likely to drop out, show higher rates
of attendance and have a better working alliance with the thera-
pist (Elkin et al., 1999; Iacoviello et al., 2007; Kwan et al., 2010;
Raue et al., 2009). These methodological problems related to
preferences may lead to a gap between results obtained in RCTs
and routine practice (TenHave et al., 2003).
To our knowledge, no studies have explicitly examined patient
preferences and their possible relation with treatment adherence
and treatment outcome in relapse/recurrence prevention of MDD.
In two parallel randomised controlled trials (the ﬁrst comparing
the combination of MBCT and mADM to MBCT alone, the second
comparing the combination to mADM alone), patients could
choose to participate in either study, according to their preference
for either mADM or MBCT. The current post-hoc study aims to
investigate: (a) possible differences in demographic and clinical
characteristics between patients with a preference for MBCT and
those with a preference for mADM; (b) whether patients’ pre-
ferences are associated with adherence to MBCT or adherence to
mADM; and (c) whether patients’ preferences are associated with
relapse/recurrence risk, severity of depressive symptoms, or
quality of life, over the 15 months follow-up. We had no speciﬁc a
priori hypotheses with regard to possible differences in patients’
baseline characteristics, but we expected MBCT treatment ad-
herence and clinical outcome to be better for patients preferringMBCT than for patients preferring mADM.2. Methods
2.1. Study design
The study design and procedures are presented in full in the
published study protocol (Huijbers et al., 2012) and are sum-
marised below. Originally we intended to conduct a three-armed
RCT of MBCT alone, mADM alone or MBCTþmADM, but due to
strong treatment preferences this turned out not to be feasible.
Therefore we ended up conducting two parallel RCTs (see Fig. 1).
Patients preferring MBCT participated in an RCT comparing the
combination of MBCT and mADM to MBCT alone, i.e. with dis-
continuation of mADM (Huijbers et al., In press). Patients pre-
ferring to continue their mADM participated in an RCT comparing
the combination of MBCT and mADM to mADM alone (Huijbers
et al., 2015). This change in design enabled us to acknowledge
patients’ preferences while maintaining the experimental rigour of
randomisation. In addition, it provided the opportunity to study
the possible effect of treatment preference in depression relapse/
recurrence prevention.
2.2. Participants and procedure
Patients were recruited in 12 secondary and tertiary psychiatric
outpatient clinics across the Netherlands between September
2009 and January 2012. Patients were referred by mental health
care professionals or recruited by advertisements in the media
(TV, magazines and newspapers). Inclusion criteria were a history
of at least three previous depressive episodes according to the
Diagnostic and Statistical Manual of Mental Disorders-4th edition
(DSM-IV), being in full or partial remission; currently treated with
mADM for at least 6 months; 18 years of age or older; and Dutch
speaking. The study was approved by the Medical Ethics Com-
mittee Arnhem-Nijmegen (nr. 2008/242) for all participating sites.
After full explanation of the study, written informed consent was
obtained from all participants. The study period was 15 months
with assessments at 0 (baseline), 3, 6, 9, 12 and 15 months. For the
possible differences between patients who preferred to participate
in trial A (preference for MBCT) and trial B (preference for medi-
cation) we used data of all participants (n¼317). For all others
analyses we only used data from the participants who received the
combination of MBCT and mADM (n¼121þ33).
2.3. Intervention: MBCT plus maintenance ADM (MBCTþmADM)
MBCT was delivered in 12 different centres across the Nether-
lands according to the, slightly adapted, protocol by Segal, Wil-
liams and Teasdale (Segal et al., 2002). It was delivered in groups
of 8–12 participants and consisted of eight weekly sessions of 2.5 h
plus one day of silent practice between the 6th and 7th session
(Kabat-Zinn, 2013). Participants were encouraged to practice
meditation at home for about an hour a day with the support of
CDs.
For continuation of mADM, a minimum of one consultation
with a psychiatrist was recommended. Psychiatrists were in-
structed to maintain or reinstate a therapeutic dosage of mADM,
and recommendations to manage side effects were provided. Ad-
herence to the mADM protocol was deﬁned as using a therapeutic
dose at each follow-up contact during the observed time period
(using last observation carried forward for participants who did
not complete all assessments).
Fig. 1. Schematic overview of the two trials and random allocation to treatments.
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Preference for MBCT was operationalised as choosing to parti-
cipate in trial A (MBCTþmADM versus MBCT alone) and pre-
ference for mADM as choosing to participate in trial B
(MBCTþmADM versus mADM alone).
Preference strength was measured at baseline with an adapted
version of the Treatment Credibility Questionnaire (TCQ; (Borko-
vec and Nau, 1972) by Addis et al. (2004), with one additional item
from the Credibility Expectancy Questionnaire (Devilly and Bor-
kovec, 2000). The TCQ that was used in this study originally con-
sisted of 7 items that focus on credibility and expectancy: “To what
extent do you think this treatment will help you?”, “How logical
does this treatment appear to you?”, “How scientiﬁc does this
treatment appear to you?”, “To what extent do you think that this
treatment will help you to better understand the causes of your
problems?”, “To what extent do you think that you will learn ef-
fective strategies to cope with your problems in this treatment?”,
“To what extent does this treatment correspond to your ideas
about what helps people in treatments?” and “To what extent do
you feel that this treatment will reduce your complaints?”. For the
current study, we excluded items 4 and 5 from the analyses be-
cause these seemed to be less applicable to mADM, resulting in an
adapted 5-item version of the scale. Items were scored on a
7-point rating scale, ranging from 1 (not at all) to 7 (very much)
with a total score ranging between 5 and 35. The TCQ was ad-
ministered for both aspects of the intervention: MBCT and mADM.
Internal consistencies in the current study were α¼ .87 for the TCQ
about MBCT and α¼ .85 for the TCQ about mADM. In the analyses,
the difference between the credibility of MBCT and that of mADM
(TCQ MBCT – TCQ mADM) was used as a predictor of treatment
outcome, referred to as “MBCT preference strength”.
2.5. Outcome measures
Adherence to MBCT included two aspects: the number of ses-
sions attended and the average percentage of days per month atwhich patients practiced at home during the ﬁrst three months.
Home practice was assessed using calendars speciﬁcally designed
for the study, on which participants could indicate their home
practice (yes or no) on a daily basis.
Adherence to mADM also included two aspects: the dichot-
omous classiﬁcation of using a therapeutic dose according to the
Dutch pharmacotherapeutic compass (Health Insurance Board,
2000) at each follow-up contact during the observed time period
(yes or no) and the average percentage of days per month at which
patients used their medication during the ﬁrst three months. This
average percentage of medication use was calculated from the
study calendars, on which patients indicated whether they had
used medication (yes or no) on a daily basis, similar to the daily
registration of mindfulness practice.
Primary outcome was relapse/recurrence as measured with the
Structured Clinical Interview for DSM (SCID-I; First et al. (1996)) by
trained research assistants every three months during the 15-
month follow-up period. The interrater reliability between ﬁrst
and second (blind) ratings was found to be substantial
(Kappa¼0.70, po .001, 95% CI 0.456–0.942).
Secondary outcomes were time to relapse/recurrence, the se-
verity of depressive symptoms during follow-up and quality of life.
The Inventory of Depressive Symptomatology – Clinician rated
(IDS-C; Rush et al. (1996)) was used to assess severity of depres-
sive symptoms at baseline, 3, 6, 9, 12 and 15 months. The IDS-C has
good psychometric qualities (Rush et al., 1996; Trivedi et al., 2004).
The internal consistency in the current study ranged between
α¼ .85 and α¼ .92 across the six assessments. Quality of life was
assessed at baseline, 3 and 15 months using the 26-item self-re-
port WHOQOL short version (The WHOQOL Group, 1998). The
WHOQOL assesses subjective quality of life in four domains:
physical, psychological, social and environmental. Two questions
with regard to overall perception of quality of life and health were
included as well.
Table 1
Baseline demographic and clinical characteristics of patients with recurrent de-
pression in remission participating in either trial A (MBCT preference; comparing
MBCTþmADM versus MBCT alone) or trial B (mADM preference; comparing
MBCTþmADM versus mADM alone).
Variable (A) MBCT pre-
ference (N¼249)
(B) mADM pre-
ference (N¼68)
Comparison
N % N % χ2 p
Female 168 67 49 72 0.52 .47
Educational level 3.68 .16
Low 17 7 8 12
Middle 65 26 23 34
High 154 62 35 51
Missing 13 5 2 3
Marital status 0.24 .89
Single 56 23 17 25
Married/
cohabiting
141 57 40 59
Divorced/
widowed
41 16 10 15
Missing 11 4 1 1
Employed 159 64 38 56 1.54 .22
Remission 0.63 .43
Full, IDS-Cr11 133 53 40 59
Partial, IDS-C411 116 47 28 41
Type of mADM 0.32 .85
SSRI 190 76 51 75
TCA 42 17 11 16
Othera 17 7 6 9
Previous CBT
treatment
148 59 35 51 1.39 .24
Suicide attempt
(lifetime)
47 19 11 16 0.27 .60
Mean SD Mean SD t p
Age (years) 50.3 10.6 51.8 14.2 0.93 .35
Baseline depres-
sion (IDS-C)
12.6 10.0 12.1 9.6 0.34 .73
Nr. previous
episodes
5.9 5.0 7.4 7.1 2.02 .045
Age at MDD onsetb 25.0 11.7 24.4 11.5 0.37 .71
MBCT preference
strengthc
1.4 5.8 2.9 7.9 3.92 .00
Mindfulness skills
(FFMQ)d
116.4 16.4 121.4 14.6 2.22 .027
MBCT¼mindfulness-based cognitive therapy; mADM¼maintenance anti-
depressant medication; IDS-C¼ Inventory of Depressive Symptomatology – Clin-
ician rated; SSRI¼selective serotonin reuptake inhibitor; TCA¼tricyclic anti-
depressant; CBT¼cognitive-behavioural therapy; MDD¼major depressive dis-
order; FFMQ¼Five Facet Mindfulness Questionnaire.
a Including serotonin-norepinephrine reuptake inhibitors, monoamine oxi-
dase-inhibitors, and mirtazapine.
b Based on self-report.
c Treatment Credibility Questionnaire (TCQ; Addis et al., 2004, Borkovec and
Nau, 1972) was assessed twice: once for MBCT and once for mADM. Reported is the
difference between these scores (TCQ MBCT – TCQ mADM), data available for
n¼225 in the MBCT preference group, and for n¼59 in the mADM preference
group.
d Total score, available for n¼228 (MBCT preference group) and n¼64 (mADM
preference group).
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All analyses were performed using IBM SPSS Statistics version
20.0 (IBM Corporation, 2011) unless stated otherwise. Probability
values lower than .05 (two-tailed) were considered signiﬁcant for
all analyses. Possible differences in baseline characteristics be-
tween participants with a preference for MBCT or mADM were
examined using independent samples t-tests for continuous and
Pearson χ2 tests for categorical variables. For these analyses, we
used data from the complete sample (N¼317). For all other ana-
lyses we used the total number of patients who received MBCT and
mADM (N¼154). Analyses were based on intention-to-treat.The association between preference type (MBCT versus mADM)
and adherence to MBCT was examined with separate ANOVAs for
(a) number of sessions and (b) percentage of home practice in the
ﬁrst three months. For MBCT preference strength as a predictor,
we used linear regression analyses for (a) number of sessions and
(b) amount of home practice, in separate analyses. The association
between preference type (MBCT versus mADM) and adherence to
mADM was examined with a Pearson Chi-square test (two-tailed)
for the dichotomous adherence measure (yes or no) and ANOVA
for the percentage of mADM adherence (days per month) in the
ﬁrst three months. MBCT preference strength was used as a pre-
dictor in a logistic regression model for the dichotomous measure
and in a linear regression model for percentage adherence.
Relapse/recurrence rates in the two preference groups were
compared with a Pearson χ2 test and differences in time to re-
lapse/recurrence were analysed using a Cox regression propor-
tional hazards model. We used the same model to examine whe-
ther MBCT preference strength was a predictor of relapse risk. The
severity of depression at baseline and the number of previous
episodes (log transformed) were included as covariates because
these factors have been consistently associated with an increased
relapse risk (Hardeveld et al., 2010). In addition, we included
baseline characteristics that were not balanced between the
groups as covariates. Patients whose follow-up data were un-
available or who did not experience a relapse/recurrence before
the end of the follow-up period were treated as censored
observations.
The course of (residual) depressive symptoms (IDS-C) during
the 15-month follow-up period was analysed using a latent
growth curve model (LGCM) in MPlus version 7 (Muthén and
Muthén, 1998) with 6 time points, a random intercept and a ran-
dom slope for preference. To examine the predictive value of
preference type and MBCT preference strength for symptom tra-
jectory, both were added as covariates to the unconditional base
model in separate analyses. In this way we could evaluate to what
extent they predicted rate of change independent of initial level of
depressive symptom severity. In both analyses, the number of
previous episodes and mindfulness skills were included as cov-
ariates. Participants who did not complete all assessments were
included in the analyses using full information maximum like-
lihood estimation for missing data.
Quality of life was analysed with a repeated measures ANOVA
for both the observed dataset (complete case analysis) and the
imputed dataset, using multiple imputation for missing data
(Asendorpf et al., 2014).3. Results
3.1. Patient preferences and associated factors
The ﬂow of participants has been described in detail in the
original publications (Huijbers et al., 2015; Huijbers et al., In press).
As shown in Fig. 1, the majority of the included patients in both
RCTs (n¼317) preferred MBCT (n¼249; 79%) and a minority pre-
ferred mADM (n¼68; 21%). Table 1 shows the comparison of
baseline demographic and clinical characteristics of those who
preferred MBCT and those who preferred mADM. The group that
preferred MBCT reported a higher MBCT preference strength (TCQ
MBCT – TCQ mADM) than the mADM preference group (Cohen’s
d¼0.69). The relation between preference type and MBCT pre-
ference strength is displayed in Fig. 2, showing that there was
considerable variability in preference strength in both preference
groups. Patients preferring mADM reported more previous epi-
sodes (d¼0.27) and, interestingly, higher baseline levels of
mindfulness skills (d¼0.31). No other differences were found
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Fig. 2. The distribution of preference strength for mindfulness-based cognitive therapy (MBCT) over maintenance antidepressant medication (mADM) in patients preferring
MBCT (n¼249) and those preferring mADM (n¼68). Distributions were similar for the subsample that was selected for the analyses of adherence and outcome.
Fig. 3. Survival curves over 15-month follow-up (65 weeks) for the mindfulness-
based cognitive therapy (MBCT) preference group (n¼121) and maintenance an-
tidepressant medication (mADM) preference group (n¼33). a Using Cox regression
analysis. HR¼hazard ratio for MBCT preference compared to mADM; CI¼conﬁ-
dence interval.
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3.2. Prognostic signiﬁcance of preference type (MBCT versus mADM)
and MBCT preference strength
3.2.1. MBCT adherence and mADM adherence
Table 2 shows the results for the comparisons between the
preference groups for adherence to treatment. There were no
differences between the groups on any of the included measures.
MBCT preference strength was not a predictor of the number of
MBCT sessions attended (β¼0.03, p¼ .70) or the amount of
home practice reported (β¼0.08, p¼ .42). It did not predict ad-
herence to mADM (odds ratio¼0.95, 95% CI¼0.89–1.01, p¼ .10) or
the percentage of adherent days per month (β¼0.15, p¼ .14)
either.
3.2.2. Primary outcome: relapse/recurrence of depression
No differences in relapse/recurrence rates were observed be-
tween the two preference groups. The relapse/recurrence rate was
39% (47/121) in the MBCT preference group and 36% (12/33) in the
mADM preference group (χ2¼0.07; p¼ .80).
As illustrated in Fig. 3, Cox regression analysis showed that
preference for MBCT or mADM, corrected for baseline depression
severity, number of previous episodes and mindfulness skills, did
not predict the time to relapse/recurrence (hazard ratio¼1.32, 95%
conﬁdence interval 0.70–2.51, p¼ .41).Table 2
Comparisons between the MBCT preference and mADM preference groups for adheren
MBCT preference
Adherence to MBCT
Number of sessions; mean (SD), median 5.9 (2.6), 7
Home practice, % of days per month; mean (SD) 0.83 (0.15)
Adherence to mADM
Adhered to protocol (yes/no); N (%) 87 (72)
mADM use, % of days per month; mean (SD) 0.95 (0.01)
MBCT¼mindfulness-based cognitive therapy; mADM¼maintenance antidepressant meIn addition, MBCT preference strength, corrected for baseline
depression severity, number of previous episodes and mindfulness
skills, did not predict time to relapse/recurrence either (hazard
ratio¼1.00, 95% conﬁdence interval 0.97–1.05, p ¼ .85).ce to treatment.
N mADM preference N Comparison
121 6.2 (2.5), 7 33 F (1152)¼0.45, p¼ .51
79 0.82 (0.13) 26 F (1103)¼0.07, p¼ .80
121 28 (85) 33 χ2¼2.30, p¼ .13
78 0.97 (0.02) 26 F (1102)¼1.54, p¼ .22
dication; SD¼standard deviation.
Fig. 4. Severity of (residual) depressive symptoms over 15-month follow-up for the
mindfulness-based cognitive therapy (MBCT) preference group (n¼121) and
maintenance antidepressant medication (mADM) preference group (n¼33). a IDS-
C¼ Inventory of Depressive Symptomatology – Clinician Rated; cut-off points for
depression severity: 0–11 none, 12–23 mild, 24–36 moderate, 37–46 severe, 47–84
very severe (Epidemiology Data Center, 2015). b Effect of preference group on the
slope of depressive symptoms using a latent growth curve model.
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The latent growth curve analysis for severity of (residual) de-
pressive symptoms (IDS-C) over the 15-month follow-up period
showed an acceptable model ﬁt for a linear growth model: com-
parative ﬁt index¼0.96, root mean square error of ap-
proximation¼0.07, standardised root mean square residual¼0.07.
As shown in Fig. 4, patients more or less maintained mild levels of
depression throughout the study period. Adding preference group,
previous episodes, mindfulness skills, and intercept as predictors
to the unconditional base model showed that the course of de-
pression did not signiﬁcantly vary between the preference groups
(β¼0.08, se¼ .12, p¼ .49). In this analysis, 11 cases were ex-
cluded due to missing data on the covariates. Adding MBCT pre-
ference strength, previous episodes, mindfulness skills and inter-
cept as predictors to the unconditional base model showed that
the course of depression did not signiﬁcantly vary with MBCTTable 3
Quality of life at baseline, 3 and 15 months for the MBCT preference group (n¼121) an
Variable Baseline
Mean (SD) N
WHO-QoL – Q1: overall perception of quality of life
MBCT preference 3.5 (0.8) 113
mADM preference 3.7 (0.7) 32
WHO-QoL – Q2: overall perception of health
MBCT preference 3.4 (1.0) 113
mADM preference 3.3 (0.9) 32
WHO-QoL – physical domain
MBCT preference 24.2 (4.4) 113
mADM preference 24.3 (3.3) 32
WHO-QoL – psychological domain
MBCT preference 18.7 (3.2) 113
mADM preference 19.3 (3.2) 32
WHO-QoL – social domain
MBCT preference 9.8 (2.2) 113
mADM preference 10.4 (2.4) 32
WHO-QoL – environmental domain
MBCT preference 30.6 (4.0) 113
mADM preference 31.2 (3.8) 32
MBCT¼mindfulness-based cognitive therapy; mADM¼maintenance antidepressant me
a p-Value reported for the repeated measures analysis on preference – time interacti
b p-Value reported for the repeated measures analysis on preference – time interacpreference strength (β¼0.17, se¼ .12, p¼ .15). Cases with missing
data on any of the predictors were excluded from this analysis
(n¼13).
Table 3 shows the results for the analyses of quality of life. In
summary, there were no differences between the preference
groups with regard to quality of life.4. Discussion
The current study investigated patients’ treatment preferences
for either MBCT or mADM to prevent relapse in recurrent de-
pression, in two related RCTs. The majority of patients (79%) pre-
ferred trial A with MBCT in both study arms (MBCTþmADM or
MBCT alone) over trial B with mADM in both study arms
(MBCTþmADM or mADM alone). This ﬁnding is in accordance
with previous studies indicating that most patients prefer psy-
chological treatment or combined treatment over pharmacological
treatment alone (Steidtmann et al., 2012; van Schaik et al., 2004).
Regarding baseline characteristics of patients with different
types of treatment preferences, two previous studies suggested
that patients with more severe depressive symptoms were more
likely to prefer medication (Bedi et al., 2000; Dobscha et al., 2007).
Although we did not replicate this ﬁnding in the current study, the
higher number of previous episodes in the mADM preference
group may indicate that patients with higher vulnerability for
depression tend to stay on medication. Our ﬁnding that patients
preferring mADM reported higher levels of mindfulness might
indicate that they were more aware of, and more accepting to-
wards their vulnerability for depression.
Looking at the group of participants who had been allocated to
the combination of MBCT and mADM in both RCTs, patients with a
preference for MBCT were not less adherent to mADM or more
adherent to MBCT than those with a preference for mADM. Like-
wise, preference strength was not a predictor of adherence. Thus,
our results are not in line with previous ﬁndings that preferences
affect adherence and, consequently, internal study validity (Elkin
et al., 1999; Iacoviello et al., 2007; Kwan et al., 2010; Raue et al.,
2009). It is important to bear in mind, however, that despite dif-
ferences in MBCT preference strength, patients in the mADM triald mADM preference group (n¼33), both receiving MBCTþmADM.
3 months 15 months pa pb
Mean (SD) N Mean (SD) N
.71 .50
3.6 (0.8) 86 3.7 (0.9) 68
3.8 (0.7) 27 3.8 (0.8) 26
.53 .10
3.3 (1.0) 85 3.4 (1.1) 68
3.5 (1.1) 26 3.5 (0.9) 26
.87 .56
24.6 (4.7) 86 25.6 (4.5) 67
25.3 (3.9) 27 26.2 (4.2) 26
.70 .36
19.9 (3.6) 86 20.0 (3.8) 68
20.5 (3.3) 27 20.2 (3.6) 26
.47 .27
10.0 (2.2) 86 10.1 (2.2) 68
10.9 (1.9) 27 10.5 (2.5) 26
.56 .44
30.5 (4.2) 86 31.9 (4.0) 68
30.4 (4.0) 27 31.6 (3.5) 26
dication; WHO-QoL¼World Health Organisation Quality of Life.
on based on complete cases (n¼57 MBCT preference and n¼24 mADM preference).
tion based on imputed data.
M.J. Huijbers et al. / Journal of Affective Disorders 195 (2016) 32–3938were also interested in mindfulness. The mADM preference group
might represent a group of patients who are reluctant to dis-
continue their mADM, but actually willing to try MBCT as an add-
on-treatment. This corresponds with previous ﬁndings that a large
majority of patients preferred a combination of ADM and psy-
chotherapy (Steidtmann et al., 2012). In addition, several patients
allocated to mADM alone in trial B (Huijbers et al., 2015) did not
adhere to the protocol: they participated in MBCT anyway. This
points to the possibility that many patients actually preferred the
combination treatment. Unfortunately we only asked patients’
preferences for either MBCT or mADM, and not speciﬁcally for the
combination therapy, MBCT alone or mADM alone.
Furthermore, preference type and strength of MBCT preference
were not associated with treatment outcome. These ﬁndings cor-
respond with previous studies comparing antidepressants and
psychological interventions for MDD (Dunlop et al., 2012; Gelhorn
et al., 2011) but contrast with the results of others (Raue et al.,
2009; Swift et al., 2011). One explanation for our ﬁndings is that
the subsample of patients in our outcome analyses was allocated
to the combination of MBCT and mADM, which meant that they all
received their preferred treatment. On the other hand, the key
change from baseline was the addition of MBCT, as all patients
were already using mADM for a longer period. Therefore, one
would expect this addition of MBCT to be more beneﬁcial for pa-
tients with a preference for it. The advantage of our approach is
that patients were not demoralised by being allocated to a non-
preferred treatment. The disadvantage, within the context of our
research questions, is that the inﬂuence of patients’ preferences
may have been relatively small. In addition, different types of
study design may lead to different results. For example, our study
was different from most studies as our primary aim was preven-
tion of relapse/recurrence. Given that patients were thus in re-
mission at baseline, there was probably less room for improve-
ment in terms of depression severity and quality of life as our
secondary outcome measures. We cannot rule out the possibility
that a preference for MBCT versus mADM would affect outcome in
therapeutic studies. Nevertheless, the results of the current study
suggest that the inﬂuence of preference on the internal study
validity and outcome of MBCT (added to mADM) is limited.
This study provided a unique opportunity to investigate the
impact of patient preference on the outcome of MBCTþmADM in
remitted recurrently depressed patients. Patients from both pre-
ference groups were recruited in the same research sites and all
assessments and interventions took place in the same way by the
same people. Thus, the only apparent difference between them
was their relative preference for MBCT or mADM. Of course, the
comparisons that were made in the current study did not involve
randomly allocated groups, so these groups did indeed differ for
the number of previous episodes and level of mindfulness skills
and may have differed in other aspects we did not assess. How-
ever, as the two preference groups did not differ on adherence or
outcome, confounding factors explaining a possible difference are
not particularly relevant. Furthermore, we used a clinician-rated
instrument (IDS-C) to assess depression severity, which may be
more objective than a self-report measure.
An important limitation of the current study is that the sample
of patients with a preference for mADM was small. Hence, we may
not have been able to detect possible differences between the
groups. For example, there was some indication that patients in
the mADM preference group were somewhat more likely to ad-
here to mADM (85%) compared with the MBCT preference group
(72%). With the current sample size, we could have detected a
difference of approximately 25% with 80% power. With the actual
difference of 13%, the power was only 42%. Another limitation is
that our study population probably consisted of a selected sub-
sample of the larger population of patients with recurrent MDD.Patients not willing to take ADM at all, or those who had decided
to withdraw from them before, were not part of our sample. Si-
milarly, patients not interested in participating in MBCT will not
have opted for the trial at all, so the study participants will have
had a more than average interest in MBCT. As a consequence, it is
likely that the difference in preference strength was relatively
small in this study, compared to clinical practice. In patients with
stronger and more speciﬁc preferences, for example for MBCT
alone or mADM alone, the results of our comparison might have
been different. Moreover, we cannot exclude the possibility that
cultural or regional factors, such as attitudes towards MBCT or
mADM, or availability of MBCT also inﬂuence patients’ preferences.
Hence, our results may only be generalisable to the Dutch mental
health care system. It would be interesting to see whether our
ﬁndings can be replicated in other countries.
The fact that we did not ﬁnd an association between preference
for either MBCT or mADM and treatment outcome is, in fact, pretty
reassuring. Thus, patients who prefer to continue using their
medication and who might not have high expectations from
mindfulness may beneﬁt to the same extent from MBCT as those
who expect more. The current study also found no evidence for
the idea that the internal validity had been affected by the pa-
tients’ preference. That does not take away the fact that the ex-
ternal validity of the study may have been restricted by treatment
preferences. We cannot extrapolate our ﬁndings to patients with
stronger preferences for one of the monotherapies (i.e. MBCT
without medication, or medication alone). For obvious reasons, it
will not be easy if not impossible, to recruit these groups for future
studies on treatment preference. It would nevertheless be inter-
esting to include measures of patient preference in other studies of
MBCT, where the design or population might be different.References
Addis, M.E., Hatgis, C., Krasnow, A.D., Jacob, K., Bourne, L., Mansﬁeld, A., 2004. Ef-
fectiveness of cognitive-behavioral treatment for panic disorder versus treat-
ment as usual in a managed care setting. J. Consult. Clin. Psychol. 72, 625.
American Psychiatric Association (APA), 2010. Practice Guideline for the Treatment
of Patients with Major Depressive Disorder, 3rd ed. American Psychiatric As-
sociation (APA), Arlington, VA.
Asendorpf, J.B., VanDeSchoot, R., Denissen, J.J., Hutteman, R., 2014. Reducing bias
due to systematic attrition in longitudinal studies. The beneﬁts of multiple
imputation. Int. J. Behav. Dev 38, 453–460.
Bedi, N., Chilvers, C., Churchill, R., Dewey, M., Duggan, C., Fielding, K., Gretton, V.,
Miller, P., Harrison, G., Lee, A., Williams, I., 2000. Assessing effectiveness of
treatment of depression in primary care. Partially randomised preference trial.
Br. J. Psychiatry 177, 312–318.
Bockting, C.L., ten Doesschate, M.C., Spijker, J., Spinhoven, P., Koeter, M.W., Schene,
A.H., 2008. Continuation and maintenance use of antidepressants in recurrent
depression. Psychother. Psychosom. 77, 17–26.
Borges, S., Chen, Y.F., Laughren, T.P., Temple, R., Patel, H.D., David, P.A., Mathis, M.,
Unger, E., Yang, P., Khin, N.A., 2014. Review of maintenance trials for major
depressive disorder: a 25-year perspective from the US Food and Drug Ad-
ministration. J. Clin. Psychiatry 75, 205–214.
Borkovec, T.D., Nau, S.D., 1972. Credibility of analogue therapy rationales. J. Behav.
Ther. Exp. Psychiatry 3, 257–260.
Corrigan, P.W., Salzer, M.S., 2003. The conﬂict between random assignment and
treatment preference: implications for internal validity. Eval. Program Plan. 26,
109–121.
Devilly, G.J., Borkovec, T.D., 2000. Psychometric properties of the credibility/ex-
pectancy questionnaire. J. Behav. Ther. Exp. Psychiatry 31, 73–86.
Dobscha, S.K., Corson, K., Gerrity, M.S., 2007. Depression treatment preferences of
VA primary care patients. Psychosomatics 48, 482–488.
Dunlop, B.W., Kelley, M.E., Mletzko, T.C., Velasquez, C.M., Craighead, W.E., Mayberg,
H.S., 2012. Depression beliefs, treatment preference, and outcomes in a ran-
domized trial for major depressive disorder. J. Psychiatry Res. 46, 375–381.
Elkin, I., Yamaguchi, J., Arnkoff, D., Glass, C., Sotsky, S., Krupnick, J., 1999. “Patient-
treatment ﬁt” and early engagement in therapy. Psychother. Res. 9, 437–451.
Epidemiology Data Center, U.o.P., 2015. Inventory of Depressive Symptomatology
((IDS)) and Quick Inventory of Depressive Symptomatology (QIDS).
First, M.B., Gibbon, M., Spitzer, R.L., Williams, J.B.W., 1996. User Guide for the
Structured Clinical Interview for DSM-IV Axis 1 Disorders. American Psychiatric
Association, Washington, DC.
Gelhorn, H.L., Sexton, C.C., Classi, P.M., 2011. Patient preferences for treatment of
M.J. Huijbers et al. / Journal of Affective Disorders 195 (2016) 32–39 39major depressive disorder and the impact on health outcomes: a systematic
review. Prim. Care Companion CNS Disord. 13.
Hardeveld, F., Spijker, J., De Graaf, R., Nolen, W.A., Beekman, A.T., 2010. Prevalence
and predictors of recurrence of major depressive disorder in the adult popu-
lation. Acta Psychiatr. Scand. 122, 184–191.
Health Insurance Board, 2000. Pharmacotherapeutic Compass 2000/2001.
Amstelveen.
Huijbers, M.J., Spijker, J., Donders, A.R., van Schaik, D.J., van Oppen, P., Ruhe, H.G.,
Blom, M.B., Nolen, W.A., Ormel, J., van der Wilt, G.J., Kuyken, W., Spinhoven, P.,
Speckens, A.E., 2012. Preventing relapse in recurrent depression using mind-
fulness-based cognitive therapy, antidepressant medication or the combina-
tion: trial design and protocol of the MOMENT study. BMC Psychiatry 12, 125.
Huijbers, M.J., Spinhoven, P., Spijker, J., Ruhe, H.G., van Schaik, D.J., van Oppen, P.,
Nolen, W.A., Ormel, J., Kuyken, W., van der Wilt, G.J., Blom, M.B., Schene, A.H.,
Donders, A.R., Speckens, A.E., 2015. Adding mindfulness-based cognitive ther-
apy to maintenance antidepressant medication for prevention of relapse/re-
currence in major depressive disorder: Randomised controlled trial. J. Affect.
Disord. 187, 54–61.
Huijbers, M.J., Spinhoven, P., Spijker, J., Ruhé, H.G., van Schaik, D.J., van Oppen, P.,
Nolen, W.A., Ormel, J., Kuyken, W., van der Wilt, G.J., Blom, M.B., Schene, A.H.,
Donders, A.R., Speckens, A.E., 2016. Discontinuation of antidepressant medi-
cation after mindfulness-based cognitive therapy for recurrent depression:
randomised controlled non-inferiority trial. Br. J. Psychiatry (In press).
Iacoviello, B.M., McCarthy, K.S., Barrett, M.S., Rynn, M., Gallop, R., Barber, J.P., 2007.
Treatment preferences affect the therapeutic alliance: implications for rando-
mized controlled trials. J. Consult. Clin. Psychol. 75, 194–198.
IBM Corporation, 2011. IBM SPSS Statistics for Windows. IBM Corporation, Armonk,
New York.
Kabat-Zinn, J., 2013. Full Catastrophe Living: Using The Wisdom of Your Body and
Mind to Face Stress, Pain, and Illness. Bantam Books, New York.
Kaymaz, N., van Os, J., Loonen, A.J., Nolen, W.A., 2008. Evidence that patients with
single versus recurrent depressive episodes are differentially sensitive to
treatment discontinuation: a meta-analysis of placebo-controlled randomized
trials. J. Clin. Psychiatry 69, 1423–1436.
Kuyken, W., Byford, S., Taylor, R.S., Watkins, E., Holden, E., White, K., Barrett, B.,
Byng, R., Evans, A., Mullan, E., Teasdale, J.D., 2008. Mindfulness-based cognitive
therapy to prevent relapse in recurrent depression. J. Consult. Clin. Psychol. 76,
966–978.
Kuyken, W., Hayes, R., Barrett, B., Byng, R., Dalgleish, T., Kessler, D., Lewis, G.,
Watkins, E.R., Brejcha, C., Cardy, J., Causley, A., Cowderoy, S., Evans, A., Gra-
dinger, F., Kaur, S., Lanham, P., Morant, N., Richards, J., Shah, P., Sutton, H.,
Vicary, R., Weaver, A., Wilks, J., Williams, M., Taylor, R.S., Byford, S., 2015. Ef-
fectiveness and cost-effectiveness of mindfulness-based cognitive therapy
compared with maintenance antidepressant treatment in the prevention of
depressive relapse or recurrence (PREVENT): a randomised controlled trial.
Lancet 386, 63–73.
Kwan, B.M., Dimidjian, S., Rizvi, S.L., 2010. Treatment preference, engagement, and
clinical improvement in pharmacotherapy versus psychotherapy for depres-
sion. Behav. Res. Ther. 48, 799–804.
Moradveisi, L., Huibers, M., Renner, F., Arntz, A., 2014. The inﬂuence of patients’preference/attitude towards psychotherapy and antidepressant medication on
the treatment of major depressive disorder. J. Behav. Ther. Exp. Psychiatry 45,
170–177.
Muthén, L., Muthén, B., 1998. MPlus (Version 7.0) [Computer Software]. Los An-
geles, CA: Muthen and Muthen.
Piet, J., Hougaard, E., 2011. The effect of mindfulness-based cognitive therapy for
prevention of relapse in recurrent major depressive disorder: a systematic re-
view and meta-analysis. Clin. Psychol. Rev. 31, 1032–1040.
Raue, P.J., Schulberg, H.C., Heo, M., Klimstra, S., Bruce, M.L., 2009. Patients’ de-
pression treatment preferences and initiation, adherence, and outcome: a
randomized primary care study. Psychiatr. Serv. 60, 337–343.
Richards, D., 2011. Prevalence and clinical course of depression: a review. Clin.
Psychol. Rev. 31, 1117–1125.
Rush, A.J., Gullion, C.M., Basco, M.R., Jarrett, R.B., Trivedi, M.H., 1996. The Inventory
of Depressive Symptomatology (IDS): psychometric properties. Psychol. Med.
26, 477–486.
Rutherford, B.R., Wager, T.D., Roose, S.P., 2010. Expectancy and the treatment of
depression: a review of experimental methodology and effects on patient
outcome. Curr. Psychiatry Rev. 6, 1.
Segal, Z.V., Bieling, P., Young, T., MacQueen, G., Cooke, R., Martin, L., Bloch, R., Le-
vitan, R.D., 2010. Antidepressant monotherapy vs sequential pharmacotherapy
and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in
recurrent depression. Arch. Gen. Psychiatry 67, 1256–1264.
Segal, Z.V., Williams, J.M.G., Teasdale, J.D., 2002. Mindfulness-Based Cognitive
Therapy for Depression: A New Approach to Relapse Prevention. Guilford Press,
New York.
Segal, Z.V., Williams, J.M.G., Teasdale, J.D., 2012. Mindfulness-Based Cognitive
Therapy for Depression, 2nd ed. Guilford Press, New York.
Steidtmann, D., Manber, R., Arnow, B.A., Klein, D.N., Markowitz, J.C., Rothbaum, B.O.,
Thase, M.E., Kocsis, J.H., 2012. Patient treatment preference as a predictor of
response and attrition in treatment for chronic depression. Depress. Anxiety 29,
896–905.
Swift, J.K., Callahan, J.L., Vollmer, B.M., 2011. Preferences. J. Clin. Psychol. 67,
155–165.
TenHave, T.R., Coyne, J., Salzer, M., Katz, I., 2003. Research to improve the quality of
care for depression: alternatives to the simple randomized clinical trial. Gen.
Hosp. Psychiatry 25, 115–123.
The WHOQOL Group, 1998. Development of the World Health Organization
WHOQOL-BREF quality of life assessment. Psychol. Med. 28,551-558.
Trivedi, M.H., Rush, A.J., Ibrahim, H.M., Carmody, T.J., Biggs, M.M., Suppes, T., Cris-
mon, M.L., Shores-Wilson, K., Toprac, M.G., Dennehy, E.B., Witte, B., Kashner, T.
M., 2004. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-
C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Sympto-
matology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector
patients with mood disorders: a psychometric evaluation. Psychol. Med. 34,
73–82.
van Schaik, D., Klijn, A., van Hout, H., van Marwijk, H., Beekman, A., de Haan, M., van
Dyck, R., 2004. Patients’ preferences in the treatment of depressive disorder in
primary care. Gen. Hosp. Psychiatry 26, 184–189.
